This is a standard Form 3 filing with no trading activity or change in position. Monitor for subsequent Form 4 filings if Novo Holdings buys or sells shares post-IPO, which could signal conviction changes. The large convertible stake indicates Novo Holdings is a key insider with potential influence on corporate governance.
Price Chart
Executive Summary
Novo Holdings A/S filed a Form 3 initial statement of beneficial ownership, disclosing holdings in Hemab Therapeutics (COAG) ahead of its IPO. The filing shows Novo Holdings beneficially owns 513,546 shares of Common Stock and convertible preferred shares (Series Seed, A, B, C) that convert to Common Stock on a 22-for-1 basis at IPO closing, totaling approximately 4,177,550 common-equivalent shares. This signals Novo Holdings' significant pre-IPO stake but provides no new financial data or trading activity.
Key Facts
- Novo Holdings A/S filed Form 3 as an initial beneficial ownership report for Hemab Therapeutics Holdings, Inc. (COAG).
- Novo Holdings directly owns 513,546 shares of Common Stock.
- Novo Holdings also holds Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock, each convertible into Common Stock on a 22-for-1 basis immediately prior to the IPO closing.
- The convertible preferred shares represent approximately 3,664,004 common-equivalent shares (1581052 + 1366662 + 719290 + 0 for Series Seed? Actually Series Seed amount not given in the XML snippet, but the total from the listed preferred series is 1581052 + 1366662 + 719290 = 3,664,004). Combined with the 513,546 common shares, total beneficial ownership is approximately 4,177,550 common-equivalent shares.
- The filing is dated April 30, 2026, and is a routine initial ownership disclosure required under Section 16(a) of the Securities Exchange Act of 1934.
- No transactions or changes in ownership are reported; this is a snapshot of holdings as of the filing date.
Financial Impact
No financial impact; the filing is a routine disclosure of pre-IPO beneficial ownership by a major shareholder.
Risk Factors
- No material risks identified from this filing alone; it is a routine disclosure.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001388325-26-000019 |
| Document: 0001388325-26-000019-index.html | 0001388325-26-000019 |
| Document: 0001388325-26-000019.txt | 0001388325-26-000019 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $49.87 $44.50 | ▼ −10.77% | ▼ −9.71% | $30.36 (−39.12%) |
Jun 17, 2026 15w ago | Insider Buy | $29.24 $44.53 | ▲ +52.29% | ▲ +51.76% | $30.36 (+3.83%) |
May 21, 2026 19w ago | Press Release | $26.30 $31.83 | ▲ +21.03% | ▲ +20.69% | $30.36 (+15.44%) |
May 4, 2026 21w ago | 8-K | $25.00 $27.47 | ▲ +9.88% | ▲ +4.93% | $30.36 (+21.44%) |
Apr 30, 2026 22w ago | Press Release | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access